Atossa Therapeutics, Inc.

As of June 30, 2026, Atossa Therapeutics, Inc. carries a market capitalization of 341.29M, placing it among publicly traded companies globally. Its enterprise value stands at -114.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Atossa Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Atossa Therapeutics, Inc. has 9.98M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Atossa Therapeutics, Inc. maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Atossa Therapeutics, Inc. posted a negative return on equity (ROE) of -89.23, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -77.91, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 14.25, a quick read on workforce productivity versus industry peers.

As of the close on October 16, 2026, Atossa Therapeutics, Inc.'s stock has declined approximately 82.89% over the past 52 weeks. The 50-day moving average sits at 113.39, while the 200-day moving average is 239.65.

Over the twelve months ended June 30, 2026, Atossa Therapeutics, Inc. generated - - in revenue and converted that into -658.84M in net income, yielding earnings per share of -75.83. EBITDA reached -685.50M, while operating income came in at -685.78M.

These figures are as of June 30, 2026. Total book value stands at 468.76M, with working capital of 446.56M providing operational flexibility.

Atossa Therapeutics, Inc. produced -624.94M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -244,602.40 in capital expenditures, free cash flow totaled -625.19M - equivalent to -71.96 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -210.40: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.58, meaning Atossa Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Atossa Therapeutics, Inc.'s most recent stock split took place on February 4, 2026 with a 15:1 split ratio.

As of June 30, 2026, Atossa Therapeutics, Inc. has an Altman Z-Score of -12.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.